Related Experiment Video
Updated: May 13, 2026

07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
The GABPB1 gene A/G polymorphism in Polish rowers
A Maciejewska-Karłowska1, A Leońska-Duniec, P Cięszczyk
1Department of Genetics, University of Szczecin, Poland.
Journal of Human Kinetics
|March 15, 2013
Summary
The GABPB1 gene
Area of Science:
- Genetics
- Sports Science
- Molecular Biology
Background:
- Nuclear respiratory factor 2 (NRF2), also known as GA-binding protein (GABP), regulates mitochondrial enzyme genes.
- GABPB1 gene variants, specifically the A/G polymorphism (rs7181866) in intron 3, are linked to endurance performance.
- Understanding genetic predispositions for athletic success is crucial in sports science.
Purpose of the Study:
- To investigate the association between the GABPB1 A/G polymorphism (rs7181866) and physical performance in Polish rowers.
- To determine if specific genotypes or alleles of GABPB1 are more prevalent in elite endurance athletes compared to sedentary individuals.
Main Methods:
- DNA was extracted from buccal cells of 55 Polish rowers and sedentary controls.
- Genotyping of the GABPB1 A/G polymorphism (rs7181866) was performed using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
- Genotype and allele frequencies were compared between the athlete and control groups.
Main Results:
- The frequency of the GABPB1 A/G genotype was significantly higher in rowers (10.91%) compared to controls (2.31%) (P = 0.012).
- The G allele frequency was also significantly elevated in rowers (5.50%) versus controls (1.17%) (P = 0.014).
- These findings suggest a potential genetic link between GABPB1 variants and endurance capacity.
Conclusions:
- The GABPB1 gene, particularly the A/G polymorphism (rs7181866), may serve as a genetic marker for endurance athletes.
- Further research involving other GABPB1 polymorphisms and genes in elite endurance athletes is recommended to validate these findings.
- This study contributes to understanding the genetic basis of athletic performance in endurance sports.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
